DnB Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$136M Buy
626,875
+51,768
+9% +$11.5M 0.49% 36
2025
Q4
$131M Buy
575,107
+81,312
+16% +$18.5M 0.46% 35
2025
Q3
$114M Sell
493,795
-9,251
-2% -$1.88M 0.43% 36
2025
Q2
$93.4M Buy
503,046
+34,096
+7% +$6.34M 0.39% 49
2025
Q1
$98.3M Sell
468,950
-70,578
-13% -$13.7M 0.45% 46
2024
Q4
$95.9M Buy
539,528
+47
+0% +$8.64K 0.41% 38
2024
Q3
$107M Buy
539,481
+13,955
+3% +$2.6M 0.48% 37
2024
Q2
$90.1M Buy
525,526
+90,402
+21% +$15M 0.43% 40
2024
Q1
$79.2M Buy
435,124
+4,476
+1% +$771K 0.41% 42
2023
Q4
$66.7M Buy
430,648
+13,826
+3% +$2.02M 0.35% 55
2023
Q3
$62.1M Buy
416,822
+26,863
+7% +$3.94M 0.37% 55
2023
Q2
$52.5M Buy
389,959
+38,963
+11% +$5.71M 0.3% 69
2023
Q1
$55.9M Sell
350,996
-43,641
-11% -$6.67M 0.35% 60
2022
Q4
$63.8M Buy
394,637
+14,216
+4% +$2.18M 0.45% 53
2022
Q3
$51.1M Sell
380,421
-14,763
-4% -$2.12M 0.39% 56
2022
Q2
$60.5M Sell
395,184
-6,702
-2% -$1.02M 0.43% 55
2022
Q1
$65.1M Buy
401,886
+14,620
+4% +$2.12M 0.39% 55
2021
Q4
$52.4M Buy
387,266
+13,827
+4% +$1.63M 0.31% 64
2021
Q3
$40.3M Buy
373,439
+51,183
+16% +$5.85M 0.26% 80
2021
Q2
$36.3M Sell
322,256
-68,098
-17% -$7.67M 0.24% 84
2021
Q1
$42.2M Buy
390,354
+151,696
+64% +$16.2M 0.31% 56
2020
Q4
$25.6M Sell
238,658
-85,674
-26% -$8.23M 0.22% 95
2020
Q3
$28.4M Sell
324,332
-675,914
-68% -$63.6M 0.3% 64
2020
Q2
$98.2M Buy
1,000,246
+184,022
+23% +$16.2M 1.15% 17
2020
Q1
$62.2M Buy
816,224
+599,999
+277% +$51.1M 0.91% 23
2019
Q4
$19.1M Buy
216,225
+26,876
+14% +$2.23M 0.19% 94
2019
Q3
$14.3M Buy
189,349
+11,017
+6% +$755K 0.16% 109
2019
Q2
$13M Buy
178,332
+16,432
+10% +$1.29M 0.15% 109
2019
Q1
$13M Sell
161,900
-15,901
-9% -$1.3M 0.15% 115
2018
Q4
$16.4M Sell
177,801
-10,384
-6% -$913K 0.21% 87
2018
Q3
$17.8M Buy
188,185
+1,190
+0.6% +$113K 0.2% 87
2018
Q2
$17.3M Buy
186,995
+4,500
+2% +$439K 0.2% 87
2018
Q1
$17.3M Buy
182,495
+14,600
+9% +$1.6M 0.21% 94
2017
Q4
$16.2M Buy
167,895
+2,600
+2% +$245K 0.2% 91
2017
Q3
$14.7M Sell
165,295
-6,100
-4% -$464K 0.2% 93
2017
Q2
$12.4M Sell
171,395
-1,000
-0.6% -$67.2K 0.18% 96
2017
Q1
$11.2M Buy
172,395
+17,900
+12% +$1.13M 0.18% 103
2016
Q4
$9.67M Buy
154,495
+8,900
+6% +$543K 0.18% 110
2016
Q3
$9.18M Buy
145,595
+8,800
+6% +$570K 0.18% 112
2016
Q2
$8.47M Sell
136,795
-68,586
-33% -$4.18M 0.18% 109
2016
Q1
$11.7M Buy
205,381
+300
+0.1% +$16.7K 0.25% 92
2015
Q4
$12.1M Buy
205,081
+48,700
+31% +$2.8M 0.26% 78
2015
Q3
$8.51M Buy
156,381
+4,300
+3% +$280K 0.21% 91
2015
Q2
$10.2M Sell
152,081
-816,261
-84% -$53.3M 0.23% 89
2015
Q1
$56.7M Buy
968,342
+845,380
+688% +$51.1M 1.26% 21
2014
Q4
$8.05M Buy
122,962
+12,200
+11% +$769K 0.18% 108
2014
Q3
$6.4M Buy
110,762
+29,500
+36% +$1.64M 0.14% 117
2014
Q2
$4.59M Buy
+81,262
New +$4.26M 0.1% 144
2013
Q4
$3M Sell
56,876
-24,600
-30% -$1.21M 0.07% 150
2013
Q3
$3.64M Sell
81,476
-400
-0.5% -$17.7K 0.1% 106
2013
Q2
$3.38M Buy
+81,876
New +$3.58M 0.1% 100

Other funds holding ABBV

DnB Asset Management's ABBV Position: Q1 2026 in Review

DnB Asset Management increased its AbbVie (ABBV) stake by 9% in Q1 2026, buying an estimated $11.5M and bringing the position to 626,875 shares worth $136M. The position accounts for 0.49% of the portfolio, ranked #36.

DnB Asset Management first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • DnB Asset Management held 626,875 shares of AbbVie worth $136M as of Q1 2026.
  • DnB Asset Management bought 51,768 AbbVie shares in Q1 2026, an estimated $11.5M.
  • AbbVie made up 0.49% of DnB Asset Management's portfolio in Q1 2026, its #36 holding.
  • DnB Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.